Comparative Pharmacology
Head-to-head clinical analysis: CUPRIMINE versus EDETATE CALCIUM DISODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CUPRIMINE versus EDETATE CALCIUM DISODIUM.
CUPRIMINE vs EDETATE CALCIUM DISODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chelates copper, forming a stable complex that is excreted renally, reducing systemic copper accumulation.
Chelates heavy metals (e.g., lead, cadmium) by forming stable complexes with divalent and trivalent cations, which are then excreted in urine.
250-500 mg orally 4 times daily, titrated to maintain urinary copper excretion >2 mg/day. Maximum: 2 g/day.
Edetate calcium disodium is administered intravenously or intramuscularly. For lead poisoning: 1000 mg/m²/day IV continuous infusion or in divided doses every 12 hours; alternatively 50 mg/kg/day IV or IM in divided doses every 8-12 hours. Maximum 3000 mg/day. Duration typically 5 days, repeat after 2 days rest. For other heavy metal toxicity: 50 mg/kg/day IV or IM in divided doses every 8-12 hours for 3-5 days.
None Documented
None Documented
Terminal half-life: 4–6 hours. Clinical context: After discontinuation, urinary copper excretion declines within 2–3 hours but may persist for several days due to tissue redistribution.
Terminal elimination half-life approximately 1.5-3 hours for the intact chelate; prolonged to 20-40 hours in lead-intoxicated patients due to redistribution of lead from bone.
Renal: ~80% as unchanged drug, biliary/fecal: <5%
Primarily renal (90-100% as chelated lead complex within 24-48 hours); minimal biliary/fecal excretion (<5%).
Category C
Category C
Chelating Agent
Chelating Agent